VivoSeq
Other

Itching

0

Pipeline Programs↗

4

Active Trials↗

6

Companies Involved↗

Itching is an early-stage landscape with 0 programs across 6 companies. The most active players are Gilead, Bristol-Myers Squibb, Bayer.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalK

Korea Otsuka Pharmaceutical Co., Ltd.

0 programs

PreclinicalUCB logo

UCB

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

49

clinical trials

Completed36 · 73%
Unknown status5 · 10%
Terminated4 · 8%
Not yet recruiting3 · 6%
Recruiting1 · 2%

Clinical Trials

Trial Activity

49 trials

Switching of Sildenafil to Riociguat in CTEPH Patients
Recruiting·—·Phase 4·NCT06715280·30 enrolled
Switching From Restasis to TRYPTYR
Not yet recruiting·SSouthern College of Optometry·Phase 4·NCT07267299·100 enrolled
Switching From Xiidra to TRYPTYR
Not yet recruiting·SSouthern College of Optometry·Phase 4·NCT07267481·100 enrolled
Study on the Preventive and Therapeutic Effects and Mechanism of Transcranial Direct Current Stimulation on Morphine-Induced Itching After Cesarean Section: A Randomized Clinical Controlled Trial
Not yet recruiting·AAffiliated Hospital of Nantong University·Preclinical·NCT07569783·104 enrolled
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Completed·UUniversity of Florida·N/A·NCT02016170·82 enrolled
HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen
Completed·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT02513147·44 enrolled
Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis
Completed·RRetina Institute of Hawaii·N/A·NCT00804934·100 enrolled
Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA
Completed·YYonsei University·Phase 4·NCT00625339·72 enrolled
Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes
Completed·RRose Research Center, LLC·Phase 3·NCT04388319·26 enrolled
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
Completed·Gilead logoGilead·Phase 3·NCT01815736·1,443 enrolled
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
Completed·—·Phase 3·NCT03311945·33 enrolled
Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir
Completed·HHelsinki University Central Hospital·Phase 4·NCT03374358·45 enrolled
Metabolic Effects of Switching Kaletra to Boosted Reyataz
Completed·MMassachusetts General Hospital·N/A·NCT00413153·15 enrolled
Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies
Completed·Bayer logoBayer·N/A·NCT03405337·160 enrolled
Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT00135382·254 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)